드러그인포 약품요약정보

허가정보

항목

내용

청구코드(KD코드)
비급여점검코드
상한금액

660701480 [보험코드에 따른 약품기본정보 직접조회]
[비급여]
[상병코드조회]
[질병코드조회]

빠른조회


요약정보	[효능] [용법] [금기] [신중투여] [이상반응]

상세정보	[효능] [용법] [경고] [금기] [신중투여] [이상반응] [일반주의] [상호작용] [임산부] [수유부] [소아] [고령자] [신장애환자] [간장애환자] [적용주의] [과량투여] [임상검사치] [보관] [기타]

주성분코드

557600CCM [동일한 주성분코드를 가진 오리지날 또는 제네릭 의약품 조회]

효능효과

[적응증 별 검색]

중등도의 심상성 여드름의 국소치료. 염증성 및 비염증성 병변의 치료

약물음식간 상호작용

[조회]

용법용량

* 절대 임의복용하지 마시고 반드시 의사 또는 약사와 상담하시기 바랍니다.

[처방약어]
하루에 한번 또는 두 번 전체 병변 부위에 얇게 바른다. 피부에 적용하기 전에 충분히 씻은 다음 건조시켜야 한다. 치료 효과는 6 ~ 8주 사용 후 나타난다.
여드름이 거의 드문 사춘기 이전의 소아에 대한 용법, 용량은 설정되어 있지 않다

[BMI지수 계산] [Body Surface Area 계산] [Cockcroft-Gault GFR 계산] [MDRD GFR 계산]

주요약물 상호작용

[조회]

금기

1) 이 약 또는 이 약 성분에 과민반응의 병력이 있는 환자
2) 일광화상 환자(태양광선에 대한 감수성이 증가될 수 있으므로 완전히 회복될 때까지 이 약을 사용하지 않는다)
3) 임부 또는 임신하고 있을 가능성이 있는 여성 및 수유부

신중투여

1) 피부암 병력 또는 가족력이 있는 환자
2) 광알레르기 반응의 병력이 있는 환자
3) 국소소장염, 궤양성대장염, 항생제 관련 대장염(가성막대장염 포함) 또는 그 병력이 있는 환자

이상반응

1) 피부 및 피하조직: 적용부위에 홍반, 피부박리, 피부통증, 적용부위에 소양증, 피부자극감, 피부압통, 피부작열감, 적용부위에 자통, 피부건조감, 발진이 매우 흔하게 나타날 수 있다. 시판 후 임상에서 습진, 박탈피부염, 피부건조이 흔하게 나타났으며, 피부변색, 피부과다색소침착, 피부색소침착저하, 광민감반응, 두드러기가 드물게 나타났다.
2) 면역계 : 드물게 알레르기 반응
3) 소화계 : 드물게 복부불쾌감, 상복부 통증, 설사
4) 기타 : 얼굴 부종

[주요 이상반응정보]

Off-label Usage

[조회]

Related FDA Approved Drug

기준 성분:ISOTRETINOIN
ACCUTANE (ISOTRETINOIN)
AMNESTEEM (ISOTRETINOIN)
CLARAVIS (ISOTRETINOIN)
SOTRET (ISOTRETINOIN)
기준 성분:ERYTHROMYCIN
A/T/S (ERYTHROMYCIN)
AKNE-MYCIN (ERYTHROMYCIN)
BENZAMYCIN (BENZOYL PEROXIDE; ERYTHROMYCIN)
BENZAMYCIN PAK (BENZOYL PEROXIDE; ERYTHROMYCIN)
BRISTAMYCIN (ERYTHROMYCIN STEARATE)
C-SOLVE-2 (ERYTHROMYCIN)
E.E.S. (ERYTHROMYCIN ETHYLSUCCINATE)
E.E.S. 200 (ERYTHROMYCIN ETHYLSUCCINATE)
E.E.S. 400 (ERYTHROMYCIN ETHYLSUCCINATE)
E-BASE (ERYTHROMYCIN)
E-GLADES (ERYTHROMYCIN)
EMGEL (ERYTHROMYCIN)
E-MYCIN (ERYTHROMYCIN)
E-MYCIN E (ERYTHROMYCIN ETHYLSUCCINATE)
ERYC (ERYTHROMYCIN)
ERYC 125 (ERYTHROMYCIN)
ERYC SPRINKLES (ERYTHROMYCIN)
ERYCETTE (ERYTHROMYCIN)
ERYDERM (ERYTHROMYCIN)
ERYGEL (ERYTHROMYCIN)
ERYMAX (ERYTHROMYCIN)
ERYPAR (ERYTHROMYCIN STEARATE)
ERYPED (ERYTHROMYCIN ETHYLSUCCINATE)
ERY-TAB (ERYTHROMYCIN)
ERYTHRA-DERM (ERYTHROMYCIN)
ERYTHROCIN (ERYTHROMYCIN LACTOBIONATE)
ERYTHROCIN STEARATE (ERYTHROMYCIN STEARATE)
ERYTHROMYCIN (ERYTHROMYCIN)
ERYTHROMYCIN AND BENZOYL PEROXIDE (BENZOYL PEROXIDE; ERYTHROMYCIN)
ERYTHROMYCIN ESTOLATE (ERYTHROMYCIN ESTOLATE)
ERYTHROMYCIN ETHYLSUCCINATE (ERYTHROMYCIN ETHYLSUCCINATE)
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL (ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL)
ERYTHROMYCIN LACTOBIONATE (ERYTHROMYCIN LACTOBIONATE)
ERYTHROMYCIN STEARATE (ERYTHROMYCIN STEARATE)
ERYTHRO-STATIN (ERYTHROMYCIN)
ERYZOLE (ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL)
E-SOLVE 2 (ERYTHROMYCIN)
ETHRIL 250 (ERYTHROMYCIN STEARATE)
ETHRIL 500 (ERYTHROMYCIN STEARATE)
ILOSONE (ERYTHROMYCIN ESTOLATE)
ILOSONE SULFA (ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL)
ILOTYCIN (ERYTHROMYCIN)
ILOTYCIN GLUCEPTATE (ERYTHROMYCIN GLUCEPTATE)
PCE (ERYTHROMYCIN)
PEDIAMYCIN (ERYTHROMYCIN ETHYLSUCCINATE)
PEDIAMYCIN 400 (ERYTHROMYCIN ETHYLSUCCINATE)
PEDIAZOLE (ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL)
PFIZER-E (ERYTHROMYCIN STEARATE)
ROBIMYCIN (ERYTHROMYCIN)
R-P MYCIN (ERYTHROMYCIN)
SANSAC (ERYTHROMYCIN)
STATICIN (ERYTHROMYCIN)
T-STAT (ERYTHROMYCIN)
WYAMYCIN E (ERYTHROMYCIN ETHYLSUCCINATE)
WYAMYCIN S (ERYTHROMYCIN STEARATE)

정보요약

드럭인포 의약품 요약/상세정보

코드 및 분류정보

항목	내용
주성분코드	557600CCM [동일한 주성분코드를 가진 오리지날 또는 제네릭 의약품 조회]
BIT 약효분류	여드름치료제 (Acne Prep.)
ATC 코드	Isotretinoin, combinations / D10AD54 [코드분류상세설명] [ATC코드예측]
복지부분류코드	265 (기생성 피부질환용제 )
Drugs By Indication	[전체보기]
Drugs By Classification	[전체보기]

제품정보

항목	내용
청구코드(KD코드) 비급여점검코드 상한금액	660701480 [보험코드에 따른 약품기본정보 직접조회] [비급여] [상병코드조회] [질병코드집 다운로드]

복약정보

항목

내용

LACTmed 바로가기

[바로가기]

약리작용

유료정보입니다.

복약지도

유료정보입니다.

임부에대한투여

*	전체임신 기간별로 여러등급이 존재할 수 있으며 가장 위험도가 높은 정보만 보여집니다. 단, 복합제의 경우 모든 복합제성분에 대한 임부투여등급이 표시된것은 절대 아니며 표시된것중에 가장 위험도가 높은 정보만 나타납니다.

FDA : X등급
(isotretinoin; )

*	상기 임부투여에 대한 정보는 전산처리 되면서 입력 오류 가능성이 존재합니다. 오류 가능성을 최소화하기 위하여 많은 노력을 기울이고 있으나, 그 정확성에 대하여 확신을 드릴 수 없습니다. 이에 대해 회사는 책임을 지지 않습니다.
*	반드시 공신력 있는 문헌을 다시 한번 참고 하시기 바라며 의사 또는 약사의 판단에 따라 투여여부가 결정되어야 합니다.

신장애, 간장애시
용량조절

유료정보입니다.

Pharmacokinetics

유료정보입니다.

복약라벨

이미지

복약설명

임산부 또는 임신계획중 복용금지

*	복약이미지는 모든 복약지도 사항을 표시한것은 아니며, 추가적으로 업데이트되거나 수정될 수 있습니다.
*	복약이미지의 표시여부는 실제 약물복용시 중요도에 따른것은 아니며 단순히 허가정보상 키워드를 기준으로 등록되었습니다.
*	귀하가 복약이미지 정보를 신뢰함은 전적으로 귀하의 책임입니다. 드럭인포는 이에 대한 어떠한 보증도 하지 않습니다.

보관상 주의

조제시 주의

심사정보

항목	내용
DUR 관련 고시	[병용연령금기 의약품 / 임부금기 의약품 / 비용효과적 함량 의약품 / 안전성 관련 급여중지 의약품]

학술정보

항목	내용
DUR (의약품사용평가)	병용금기 : 고시된 병용금기 내용은 없습니다. [상호작용/병용금기검색] 연령대금기 : 고시된 연령금기 내용은 없습니다. [연령대금기상세검색]
독성정보	Isotretinoin에 대한 독성정보 : 정보보기 출처: 국립독성과학원 독성물질정보DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do
Mechanism of Action	Erythromycin에 대한 Mechanism_Of_Action 정보 Erythromycin acts by penetrating the bacterial cell membrane and reversibly binding to the 50 S subunit of bacterial ribosomes or near the “P” or donor site so that binding of tRNA (transfer RNA) to the donor site is blocked. Translocation of peptides from the “A” or acceptor site to the “P” or donor site is prevented, and subsequent protein synthesis is inhibited. Erythromycin is effective only against actively dividing organisms. The exact mechanism by which erythmromycin reduces lesions of acne vulgaris is not fully known: however, the effect appears to be due in part to the antibacterial activity of the drug. Isotretinoin에 대한 Mechanism_Of_Action 정보 Isotretinoin noticeably reduces the production of sebum and shrinks the sebaceous glands. It stabilises keratinization and prevents comedones from forming. The exact mechanism of action is unknown, however it is known that it alters DNA transcription.
Pharmacology	Erythromycin에 대한 Pharmacology 정보 Erythromycin is produced by a strain of Streptomyces erythraeus and belongs to the macrolide group of antibiotics. After absorption, erythromycin diffuses readily into most body fluids. In the absence of meningeal inflammation, low concentrations are normally achieved in the spinal fluid, but the passage of the drug across the blood-brain barrier increases in meningitis. Erythromycin is excreted in breast milk. The drug crosses the placental barrier, but fetal plasma levels are low. Erythromycin is not removed by peritoneal dialysis or hemodialysis. Isotretinoin에 대한 Pharmacology 정보 Isotretinoin, a retinoid, is indicated in the treatment of severe recalcitrant nodular acne. Nodules are inflammatory lesions with a diameter of 5 mm or greater. The nodules may become suppurative or hemorrhagic. "Severe," by definition, means "many" as opposed to "few or several" nodules. Clinical improvement in nodular acne patients occurs in association with a reduction in sebum secretion. The decrease in sebum secretion is temporary and is related to the dose and duration of treatment with Accutane, and reflects a reduction in sebaceous gland size and an inhibition of sebaceous gland differentiation.
Protein Binding	Erythromycin에 대한 단백결합 정보 Erythromycin is largely bound to plasma proteins, and the freely dissociating bound fraction after administration of erythromycin base represents 90% of the total erythromycin absorbed. Isotretinoin에 대한 단백결합 정보 99.9%
Half-life	Erythromycin에 대한 반감기 정보 1.5 hours Isotretinoin에 대한 반감기 정보 17-50 hours
Absorption	Erythromycin에 대한 Absorption 정보 Orally administered erythromycin base and its salts are readily absorbed in the microbiologically active form. Topical application of the ophthalmic ointment to the eye may result in absorption into the cornea and aqueous humor.
Pharmacokinetics	Isotretinoin의 약물동력학자료 흡수 : 음식물이나 우유에 의해 흡수가 증가한다. 생체내이용률 : 경구 : 23-25% 분포 : 태반 통과, 유즙 분비 분포용적 : 1.5 L/kg 단백결합 : 99.9% 대사 : 간대사 주 활성형 대사체는 4-oxo-isotretinoin이며 기타 tretinoin, 4-oxo-tretinoin 등의 대사체가 존재한다. 투여 6시간 이후에는 4-oxo-isotretinoin의 혈중농도가 isotretinoin의 혈중농도보다 높다. 반감기 : Isotretinoin : 10-20 시간 4-oxo-isotretinoin : 17-50 시간 (평균 25시간) 혈중최고농도 도달시간 : Isotretinoin : 약 3시간 4-oxo-isotretin Erythromycin의 약물동력학자료 흡수 : 다양하지만 base 형태보다 염의 형태가 더 잘 흡수된다. 일반적으로 음식물 존재시 흡수가 지연되나 ethylsuccinate염은 식직후에 복용하면 흡수가 증가된다. 흡수률의 차이로 erythromycin ethylsuccinate 200 mg는 erythromycin base 125 m와 동등한 혈중농도를 나타낸다. 생체내이용률 : 경구 : 18-45% 분포 : 태반통과, 유즙분비 뇌척수액으로의 분포는 염증이 있는 경우에도 미미하다. 뇌척수액 대 혈액의 농도 비 (%) : 정상 뇌막 : 1-12 감염된 뇌막 : 7-25 단백결합 : 75-90% 대사 : 간에서 demethylation 반감기 : 1.5-2 시간 말기 신부전환자 : 5-6 시간 혈중최고농도 도달시간 : base : 4시간 Ethylsuccinate 염 : 0.5-2.5 시간 소실 : 대부분 담즙배설되고, 2-15%가 미변화체로 신배설
Biotransformation	Erythromycin에 대한 Biotransformation 정보 Hepatic. Extensively metabolized - after oral administration, less than 5% of the administered dose can be recovered in the active form in the urine. Isotretinoin에 대한 Biotransformation 정보 Not Available
Toxicity	Erythromycin에 대한 Toxicity 정보 Symptoms of overdose include diarrhea, nausea, stomach cramps, and vomiting. Isotretinoin에 대한 Toxicity 정보 Not Available
Drug Interactions	Erythromycin에 대한 Drug_Interactions 정보 Alfentanil The macrolide increases the effect and toxicity of alfentanilAlprazolam The macrolide increases the effect of the benzodiazepineAminophylline The macrolide increases the effect and toxicity of theophyllineAmiodarone Increased risk of cardiotoxicity and arrhythmiasAnisindione The macrolide increases anticoagulant effectAprepitant This CYP3A4 inhibitor increases effect and toxicity of aprepitantAstemizole Increased risk of cardiotoxicity and arrhythmiasAtorvastatin The macrolide possibly increases the statin toxicityBretylium Increased risk of cardiotoxicity and arryhthmiasBromocriptine Erythromycin increases serum levels of bromocriptineBuspirone The macrolide increases the effect and toxicity of buspironeCabergoline Erythromycin increases serum levels and toxicity of cabergolineCarbamazepine The macrolide increases the effect of carbamazepineCerivastatin The macrolide possibly increases the statin toxicityCilostazol Erythromycin increases the effect of cilostazolCinacalcet This macrolide increases the serum levels and toxicity of cinacalcetCisapride Increased risk of cardiotoxicity and arrhythmiasCitalopram Possible serotoninergic syndrome with this combinationClozapine Erythromycin increases the effect of clozapineColchicine Severe colchicine toxicity can occurCyclosporine The macrolide increases the effect of cyclosporineDiazepam The macrolide increases the effect of the benzodiazepineDicumarol The macrolide increases anticoagulant effectDigoxin The macrolide increases the effect of digoxin in 10% of patientsDihydroergotamine Possible ergotism and severe ischemia with this combinationDihydroergotoxine Possible ergotism and severe ischemia with this combinationDyphylline The macrolide increases the effect and toxicity of theophyllineDisopyramide Increased risk of cardiotoxicity and arrhythmiasDivalproex sodium Erythromycin increases the effect of valproic acidDocetaxel The agent increases the serum levels and toxicity of docetaxelDofetilide Increased risk of cardiotoxicity and arrhythmiasEletriptan The macrolide increases the effect and toxicity of eletriptanEplerenone This CYP3A4 inhibitor increases the effect and toxicity of eplerenoneErgotamine Possible ergotism and severe ischemia with this combinationErlotinib This CYP3A4 inhibitor increases levels/toxicity of erlotinibImatinib The macrolide increases levels of imatinibFelodipine Erythromycin increases the effect of felodipineFluoxetine Possible serotoninergic syndrome with this combinationGefitinib This CYP3A4 inhibitor increases levels/toxicity of gefitinibGrepafloxacin Increased risk of cardiotoxicity and arrhythmiasItraconazole The macrolide increases the effect and toxicity of itraconazoleLevofloxacin Increased risk of cardiotoxicity and arrhythmiasMesoridazine Increased risk of cardiotoxicity and arrhythmiasMethylergonovine Possible ergotism and severe ischemia with this combinationLovastatin The macrolide possibly increases the statin toxicityMethylprednisolone The macrolide increases the effect of corticosteroidMethysergide Possible ergotism and severe ischemia with this combinationMidazolam The macrolide increases the efect of the benzodiazepineMoxifloxacin Increased risk of cardiotoxicity and arrhythmiasOxtriphylline The macrolide increases the effect and toxicity of theophyllinePimozide Increased risk of cardiotoxicity and arrhythmiasQuetiapine This macrolide increases the effect/toxicity of quetiapineQuinidine Increased risk of cardiotoxicity and arrhythmiasQuinidine barbiturate Increased risk of cardiotoxicity and arrhythmiasQuinupristin This combination presents an increased risk of toxicityRanolazine Increased levels of ranolazine - risk of toxicityRepaglinide This macrolide increases effect of repaglinideRifabutin The rifamycin decreases the effect of the macrolideRifampin The rifamycin decreases the effect of the macrolideRitonavir Increased toxicity of both agentsSertraline Possible serotoninergic syndrome with this combinationSibutramine Erythromycin increases the effect and toxicity of sibutramineSildenafil The macrolide increases the effect and toxicity of sildenafilSimvastatin The macrolide possibly increases the statin toxicitySirolimus The macrolide increases sirolimus levelsSotalol Increased risk of cardiotoxicity and arrhythmiasSparfloxacin Increased risk of cardiotoxicity and arrhythmiasTacrolimus Erythromycin increases the effect and toxicity of tacrolimusTerfenadine Increased risk of cardiotoxicity and arrhythmiasTheophylline The macrolide increases the effect and toxicity of theophyllineThioridazine Increased risk of cardiotoxicity and arrhythmiasVerapamil Increased risk of cardiotoxicity and arrhythmiasTriazolam The macrolide increases the effect of the benzodiazepineVardenafil The macrolide increases the effect and toxicity of vardenafilVinblastine Erythromycin increases vinblastine toxicityWarfarin The macrolide increases anticoagulant effectZafirlukast Erythromycin decreases the effect of zafirlukastErgonovine Possible ergotism and severe ischemia with this combinationEverolimus The macrolide increases everolimus levels/toxicityLincomycin Possible antagonism of action with this combinationAcenocoumarol The macrolide increases anticoagulant effect Isotretinoin에 대한 Drug_Interactions 정보 Anisindione Retinoids decreases the anticoagulant effectDicumarol Retinoids decreases the anticoagulant effectAcenocoumarol Retinoids decreases the anticoagulant effectWarfarin Retinoids decreases the anticoagulant effectCarbamazepine Isotretinoine decreases the effect of carbamazepineDemeclocycline Increased risk of intracranial hypertensionDoxycycline Increased risk of intracranial hypertensionMinocycline Increased risk of intracranial hypertensionMethacycline Increased risk of intracranial hypertensionOxytetracycline Increased risk of intracranial hypertensionTetracycline Increased risk of intracranial hypertensionRolitetracycline Increased risk of intracranial hypertension
CYP450 Drug Interaction	[CYP450 Table직접조회] Erythromycin에 대한 P450 table SUBSTRATES CYP 3A4/3A5/3A7 Macrolide antibiotics: clarithromycin erythromycin NOT azithromycin telithromycin Anti-arrhythmics: quinidine Benzodiazepines: alprazolam diazepam midazolam triazolam Immune Modulators: cyclosporine tacrolimus (FK506) HIV Protease Inhibitors: indinavir ritonavir saquinavir Prokinetic: cisapride Antihistamines: astemizole chlorpheniramine Calcium Channel Blockers: amlodipine diltiazem felodipine nifedipine nisoldipine nitrendipine verapamil HMG CoA Reductase Inhibitors: atorvastatin cerivastatin lovastatin NOT pravastatin simvastatin aripiprazole buspirone gleevec haloperidol (in part) methadone pimozide quinine NOT rosuvastatin sildenafil tamoxifen trazodone vincristine INHIBITORS CYP 3A4/3A5/3A7 HIV Protease Inhibitors: indinavir nelfinavir ritonavir amiodarone NOT azithromycin cimetidine clarithromycin diltiazem erythromycin fluvoxamine grapefruit juice itraconazole ketoconazole mibefradil nefazodone troleandomycin verapamil INDUCERS CYP 3A4/3A5/3A7 carbamazepine phenobarbital phenytoin rifabutin rifampin St. John's wort troglitazone SUBSTRATES CYP 3A4/3A5/3A7 Macrolide antibiotics: clarithromycin erythromycin NOT azithromycin telithromycin Anti-arrhythmics: quinidine Benzodiazepines: alprazolam diazepam midazolam triazolam Immune Modulators: cyclosporine tacrolimus (FK506) HIV Protease Inhibitors: indinavir ritonavir saquinavir Prokinetic: cisapride Antihistamines: astemizole chlorpheniramine Calcium Channel Blockers: amlodipine diltiazem felodipine nifedipine nisoldipine nitrendipine verapamil HMG CoA Reductase Inhibitors: atorvastatin cerivastatin lovastatin NOT pravastatin simvastatin aripiprazole buspirone gleevec haloperidol (in part) methadone pimozide quinine NOT rosuvastatin sildenafil tamoxifen trazodone vincristine INHIBITORS CYP 3A4/3A5/3A7 HIV Protease Inhibitors: indinavir nelfinavir ritonavir amiodarone NOT azithromycin cimetidine clarithromycin diltiazem erythromycin fluvoxamine grapefruit juice itraconazole ketoconazole mibefradil nefazodone troleandomycin verapamil INDUCERS CYP 3A4/3A5/3A7 carbamazepine phenobarbital phenytoin rifabutin rifampin St. John's wort troglitazone
Drug Target	[Drug Target]
Description	Erythromycin에 대한 Description 정보 Erythromycin is a bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. [PubChem] Isotretinoin에 대한 Description 정보 Isotretinoin is a medication used for the treatment of severe acne. It is sometimes used in prevention of certain skin cancers. It is a retinoid, meaning it derives from vitamin A and is found in small quantities naturally in the body. Isotretinoin binds to and activates nuclear retinoic acid receptors (RAR), thereby regulating cell proliferation and differentiation. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.
Dosage Form	Erythromycin에 대한 Dosage_Form 정보 Capsule, coated OralLiquid DentalLiquid OralOintment OphthalmicPowder IntravenousPowder OralPowder, for solution IntravenousPowder, for solution OralPowder, for suspension OralSuspension OralTablet Oral Isotretinoin에 대한 Dosage_Form 정보 Capsule Oral
Drug Category	Erythromycin에 대한 Drug_Category 정보 Anti-Bacterial Agents Isotretinoin에 대한 Drug_Category 정보 Anti-acne AgentsAntineoplastic AgentsKeratolytic AgentsSkin and Mucous Membrane Agents
Smiles String Canonical	Erythromycin에 대한 Smiles_String_canonical 정보 CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(C2O)N(C)C)C(C)(O)CC(C)C(=O)C(C)C(O)C1(C)O Isotretinoin에 대한 Smiles_String_canonical 정보 CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(O)=O
Smiles String Isomeric	Erythromycin에 대한 Smiles_String_isomeric 정보 CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O Isotretinoin에 대한 Smiles_String_isomeric 정보 CC(\C=C\C1=C(C)CCCC1(C)C)=C/C=C/C(C)=C/C(O)=O
InChI Identifier	Erythromycin에 대한 InChI_Identifier 정보 InChI=1/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1 Isotretinoin에 대한 InChI_Identifier 정보 InChI=1/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/f/h21H
Chemical IUPAC Name	Erythromycin에 대한 Chemical_IUPAC_Name 정보 (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione Isotretinoin에 대한 Chemical_IUPAC_Name 정보 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid
Drug-Induced Toxicity Related Proteins	ERYTHROMYCIN 의 Drug-Induced Toxicity Related Protein정보 Replated Protein:Misshapen-like kinase(Mink) Drug:Erythromycin Toxicity:torsade de pointes. [바로가기] Replated Protein:Potassium voltage-gated channel subfamily KQT member 1 (KvLQT1) Drug:Erythromycin Toxicity:torsade de pointes. [바로가기] Replated Protein:Intercellular adhesion molecule 1 Drug:erythromycin Toxicity:pathogenesis of infusion phlebitis. [바로가기] Replated Protein:HERG Drug:Erythromycin Toxicity:torsade de pointes. [바로가기] Replated Protein:Alanine aminotransferase Drug:erythromycin Toxicity:adverse gastrointestinal effects. [바로가기]

사용자컨텐츠

항목

내용

핵심 요약 정보